Skip to Main Content

Patient Care from Yale Medicine

Your healthcare can benefit from the breakthroughs made at the Yale School of Medicine
Our specialists
Find specialists supported by world-renowned researchers & educators.
>
See our specialists
Clinical Keyword Library
You can learn more about conditions, treatments, or procedures, or use the keyword library as a starting point to find related specialists, departments, and informational fact sheets on Yale Medicine.
>
Go to the keyword library
Referrals
Information for referring doctors
>
Refer a patient

Yale Medicine patients receive care from some of the world’s most renowned doctors.

As the clinical practice for the Yale School of Medicine, Yale Medicine’s more than 1,500 doctors play multiple roles in advancing the practice of medicine – from treating and caring for patients, to developing new cures through innovative research, to educating future doctors.

We are the largest academic multispecialty practice in New England. Our doctors and researchers work together to achieve the best care possible.

Yale Medicine offers specialist expertise, advanced and innovative technology and a multidisciplinary approach. We deliver exceptional medical care in a nurturing environment to each of our patients, every day.

Departments & Collaborative Centers

Fact Sheets

News from Yale Medicine

Clinical Trials

Leukemia

A Controlled Multi-Arm Ph1 Study Evaluating the Safety and Feasibility of TCR Engineered Donor TCells Targeting HA1 (TSC-100) or HA2 (TSC-101) in HLA-A0201 Positive Patients Undergoing Haploidentical Allogeneic Stem Cell Transplantation

AgeANY
GenderANY
Date21 August
Lymphoma

A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies

AgeANY
GenderANY
Date14 August
Breast Cancer

A First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer

AgeANY
GenderANY
Date7 February
Phase 1 Cancers

A First-In-Human, Phase 1, Dose Escalation Study of SGR-3515 In Participants With Advanced Solid Tumors

AgeANY
GenderANY
Date31 October